SinoMab BioScience Limited (HKG:3681)
Hong Kong
· Delayed Price · Currency is HKD 1.930
+0.030 (1.58%)
At close: Mar 10, 2026
SinoMab BioScience Revenue
SinoMab BioScience had revenue of 9.78M CNY in the half year ending June 30, 2025, with 15.50% growth. This brings the company's revenue in the last twelve months to 5.73M, down -659.82% year-over-year. In the year 2024, SinoMab BioScience had annual revenue of 2.03M with 48.42% growth.
Revenue (ttm)
5.73M CNY
Revenue Growth
-659.82%
P/S Ratio
426.45
Revenue / Employee
93.89K CNY
Employees
61
Market Cap
2.68B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Antengene Corporation | 92.43M |
| Jiangsu Recbio Technology | 31.90M |
| Clover Biopharmaceuticals | 56.73M |
| BioDlink International Company | 1.17B |
| Medtide | 546.29M |
| Frontage Holdings | 1.99B |
| AIM Vaccine | 1.38B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |